



# OF THE CANADIAN CO-INFECTION COHORT

2003 – 2023

A PROSPECTIVE CLINICAL COHORT OF HIV AND HEPATITIS C CO-INFECTED PATIENTS

## HOW WE STARTED

2003 – 2015 INTERFERON ERA

Low cure rates & severe physical and psychological side effects

41%

of participants received HCV treatment

55%


of those treated were cured of HCV

20%

of deaths were due to liver disease



Common HIV ART:  
Truvada + Reyataz + Norvir — 4 pills once a day



76% of participants had a suppressed HIV viral load

## WHERE WE ARE

2015 – 2022 DAA ERA

High cure rates & simplified treatment with minimal side effects

60%

of participants received HCV treatment

97%

of those treated were cured of HCV

8%

of deaths were due to liver disease




Common HIV ART:  
Triumeq or Biktarvy — 1 pill once a day




94% of participants had a suppressed HIV viral load

## WHERE WE ARE GOING

2023 POST PANDEMIC




of participants engaged in care remain to be treated



of participants who have been lost to follow-up remain to be treated


### COMPETING PRIORITIES



### WHY IS THIS WORK STILL IMPORTANT AND WHY DO WE STILL NEED YOU?



To re-engage those we've lost



To look at the long-term effects of HCV cure on health and wellbeing, including chronic conditions such as pain



the CTN  
CIHR Canadian  
HIV Trials Network

le Réseau  
Réseau canadien  
pour les essais VIH des IRSC



www.cocostudy.ca